Pamishield signs 6-year supply contract with UCB for mPEG-20k

Pamishield (파미셀) signed a 6-year contract with Belgian pharmaceutical company UCB to supply mPEG-20k, a raw material for the autoimmune disease drug Cimzia. The contract is effective from January 23, 2017, with automatic one-year renewals thereafter.

“파미셀(대표 김현수·김성래)은 벨기에 다국적 제약사 UCB사와 mPEG-20k(Methoxy-Polyethylene glycol-20k) 공급계약을 맺었다고 밝혔다.”medicaltimes.com

• 1 source
• medicaltimes.com[메디칼타임즈] 파미셀, UCB제약 원료의약품 공급 6년 계약메디칼타임즈Jan 23, 2017

Summarized from public sources; check the original articles before acting on it.